NCT02339805

Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS

Assessment of the Minimal Residual Disease in Diffuse Large B-Cell Lymphomas (DLBCL) From Cell-free Circulating DNA by Next Generation Sequencing (NGS)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Centre Henri Becquerel · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective descriptive monocentric study whose purpose is to describe the clonal evolution of the mutational pattern in cfDNA of a cohort of patients with Diffuse Large B-Cell Non-Hodgkin Lymphomas (DLBCL) before, during and after standard treatment

Detailed description

To determinate and to describe the clonal evolution, 30 DLBCL cases with available matched tumor DNA and plasma will be collected and analyzed by routinely applicable next generation sequencing (NGS) at the time of diagnosis, at mid treatment, at the end of treatment and at 12 months after diagnosis.

Conditions

• Non Hodgkin Lymphoma

Interventions

Type	Name	Description
OTHER	next generation sequencing	DNA from plasma, peripheral blood mononuclear cell and bone marrow will be sequenced by NGS for a panel of 34 genes.
DEVICE	Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)	tumor Assessment tool during the study

Timeline

• Start date: 2014-11-01
• Primary completion: 2015-07-01
• Completion: 2016-07-01
• First posted: 2015-01-15
• Last updated: 2017-07-07

Locations

1 site across 1 country: France